DelveInsight’s Injectable Drug Delivery Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Injectable Drug Delivery Devices Companies market shares, challenges, Injectable Drug Delivery Devices Market Drivers, barriers, trends, and key market Injectable Drug Delivery Devices companies in the market.
To read more about the latest highlights related to the Injectable Drug Delivery Devices Market, get a snapshot of the key highlights entailed in the Market Report @https://www.delveinsight.com/sample-request/injectable-drug-delivery-devices-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=kkpr
Key Takeaways from the Injectable Drug Delivery Devices Market Report
Becton Dickinson (BD) launched the NOVA™ prefillable syringe platform designed for advanced biologics, while West Pharmaceutical unveiled smart connected drug delivery platforms to support patient adherence.
The EMA granted clearance for Insulet’s Omnipod 5 automated wearable injector, marking a significant regulatory milestone in patient-friendly self-administration technology.
The U.S. FDA approved a supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringes, enabling self-injection across all approved U.S. indications.
The global injectable drug delivery devices market size is expected to increase from USD 570.77 billion in 2024 to USD 1,056.10 billion by 2032, reflecting strong and sustained growth.
The global injectable drug delivery devices market is growing at a CAGR of 8.10% during the forecast period from 2025 to 2032.
North America is expected to remain a dominant force in the injectable drug delivery devices market, accounting for approximately 43% of the total market share in 2024, driven by the rising prevalence of chronic diseases, strong healthcare infrastructure, favorable reimbursement policies, and high adoption of advanced self-administered therapies.
To know more about why North America is leading the market growth in the Injectable Drug Delivery Devices Market, get a snapshot @https://www.delveinsight.com/sample-request/injectable-drug-delivery-devices-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=kkpr
Injectable Drug Delivery Devices Market Dynamics
The global injectable drug delivery devices market is growing due to the rising prevalence of chronic diseases, the rapid expansion of biologics and biosimilars requiring advanced delivery systems, and continuous innovations in smart injectors, wearable devices, and needle-free technologies. According to DelveInsight, approximately 537.5 million adults aged 20–79 were living with diabetes globally, representing roughly one in ten individuals — a number projected to reach 643 million by 2030 and 783.5 million by 2045. Additionally, around 13.5 million people worldwide are affected by rheumatoid arthritis, while multiple sclerosis impacts over 2 million individuals globally. In the United States alone, approximately 38.4 million people of all ages — roughly 11.6% of the population — are affected by diabetes, with prevalence reaching 29.2% among individuals aged 65 and older. These growing patient populations, combined with the expanding biologics pipeline and increasing preference for patient-centric self-administration, are creating sustained and accelerating demand for injectable drug delivery devices worldwide.
Injectable Drug Delivery Devices Market Segmentation Analysis
This injectable drug delivery devices market report offers a comprehensive overview of the global injectable drug delivery devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product Type (Self-injectors, Needle-free Injectors, Auto-Injectors, Wearable Injectors, and Insulin Pens), Drug Loading (Pre-filled Devices and Fillable Devices), Reusability (Reusable Devices and Disposable Devices), On-Site Delivery (Intramuscular, Intradermal, and Subcutaneous), End-User (Hospitals, Specialty Clinics, and Home Care Settings), and Geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing injectable drug delivery devices market.
Injectable Drug Delivery Devices Competitive Landscape Report
The competitive landscape of the injectable drug delivery devices market is moderately concentrated, with a few leading players such as BD, West Pharmaceutical Services, and Gerresheimer holding significant market shares through their broad product portfolios, global distribution networks, and strong regulatory expertise. These companies dominate areas like prefilled syringes, safety devices, autoinjectors, and connected insulin delivery systems. At the same time, smaller and mid-sized firms — including startups such as Enable Injections, Portal Instruments, and Crossject — are driving niche innovation with wearable injectors, needle-free devices, and AI-enabled smart injectors. Strategic collaborations between pharmaceutical companies and device manufacturers are intensifying competition, while partnerships in digital health integration, sustainability, and patient-centric design are further accelerating product launches and investments in next-generation delivery systems.
Injectable Drug Delivery Devices Companies
Eli Lilly and Company, Biocon, BD, West Pharmaceutical Services, Inc., Johnson & Johnson Services, Inc., Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co. KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., and Others.
Injectable Drug Delivery Devices Market Drivers
The Injectable Drug Delivery Devices Market is growing significantly due to the growing global prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, and autoimmune conditions that require long-term injectable therapies. The rapid expansion of the biologics and biosimilars market — as most biologics cannot be administered orally and require advanced injection-based delivery — is creating significant opportunities for innovative platforms such as prefilled syringes and autoinjectors tailored for high-viscosity formulations. Rising innovation and technological advancements, including smart connected injectors with real-time dose tracking, wearable large-volume injectors, needle-free systems, and biodegradable materials, are further enhancing patient compliance and safety. Strategic collaborations between pharmaceutical companies and device manufacturers, along with growing adoption of home-care and self-administration models, are expected to further escalate demand for injectable drug delivery devices during the forecast period from 2025 to 2032.
Which MedTech key players in the Injectable Drug Delivery Devices Market are set to emerge as the trendsetters? Explore @ Injectable Drug Delivery Devices Companies
Scope of the Injectable Drug Delivery Devices Market Report
Coverage: Global
Forecast Period: 2025–2032
Key Companies in the Injectable Drug Delivery Devices Market: Eli Lilly and Company, Biocon, BD, West Pharmaceutical Services, Inc., Johnson & Johnson Services, Inc., Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co. KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation, Teva Pharmaceutical Industries Ltd., and other regional and international players.
Interested in knowing the Injectable Drug Delivery Devices Market by 2032? Click to get a snapshot of the Injectable Drug Delivery Devices Market Trends
Table of Contents
Injectable Drug Delivery Devices Market Report Introduction
Injectable Drug Delivery Devices Market Executive Summary
Injectable Drug Delivery Devices Market Key Factors Analysis
Impact Analysis
Regulatory Analysis
Injectable Drug Delivery Devices Market Porter’s Five Forces Analysis
Injectable Drug Delivery Devices Market Assessment
Competitive Landscape
Startup Funding & Investment Trends
Injectable Drug Delivery Devices Market Company and Product Profiles
KOL Views
Project Approach
About DelveInsight
Disclaimer & Contact Us
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market
